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New therapeutic strategy for recalcitrant eyelid and orbital diseasesInfantile hemangiomas are vascular tumors characterized by a
hypercellular proliferation phase and a long involutional phase.
They are the most common periorbital and orbital vascular tumors
of infancy.1 They appear shortly after birth and usually begin to invo-
lute spontaneously in early childhood. Most infantile hemangiomas
do not need to be treated, but about 20% are extremely disﬁguring
and destructive to normal tissue, which may result in amblyopia
due to astigmatism, ptosis, or globe displacement.2 Such hemangi-
omas must be treated. Therapeutic options include intralesional or
systemic corticosteroids as a ﬁrst line of treatment,3 and interferon,
vincristine, focal laser photocoagulation, and surgical excision as sec-
ondary therapeutic choices.4 In 2008, the successful effect of oral pro-
pranolol therapy on severe infantile hemangiomas was reported by
Léauté-Labrèzeet al5 inpatients treated forhypertrophiccardiomyop-
athy. Recent studies also show that nonselective b-blockers, including
systemicpropranolol and topical timolol, are apromisingnewtherapy
for infantile hemangioma.6 The mechanism of action remains uncer-
tain, but possible theories include vasoconstriction, modulation of
prosurvival signal transduction pathways, and endothelial cell
apoptosis. Potentially serious adverse effects resulting from the sys-
temic useof propranolol to treat infantile hemangioma includebrady-
cardia, hypotension, bronchospasm, hypoglycemia, and electrolyte
disturbance. More common side effects are sleep and gastrointestinal
disturbances. Topical timolol application for localized, superﬁcial tu-
mors may have similar effect as oral propranolol, while reducing sys-
temic effects. In this issue, the review article entitled “A review of
infantile capillary hemangiomas and their current treatmentmodalities”
discusses the off-label use of corticosteroids, propranolol, timolol,
vincristine, and interferon for the treatment of capillary hemangi-
omas. Christopher B. Chambers presents the classiﬁcation of capillary
hemangioma, possible complications, traditional treatment options,
and new treatment options of b blocker therapy. He also reviews the
detail dosage for systemic b blocker administration aswell as the efﬁ-
cacy and complications for this new therapeutic option.
Graves’ ophthalmopathy (GO) is an autoimmune inﬂammatory
disorder of the orbital adipose and connective tissues and the extra-
ocular muscles. This condition occurs closely in association with2211-5056/$ – see front matter Copyright  2013, The Ophthalmologic Society of Taiwa
http://dx.doi.org/10.1016/j.tjo.2013.07.001Graves’ disease, and recent evidence implicates the TSH receptor
as an important orbital autoantigen in GO.7–9 The characteristic clin-
ical manifestations of GO, including proptosis, chemosis, periorbital
edema, and extraocular muscle dysfunction, result from the intraor-
bital inﬂammatory process and the enlargement of the adipose tis-
sue and muscles within the orbit. Although the identity of the
primary autoantigens is unclear, lymphocytic inﬁltration in extraoc-
ular muscle and orbital fat tissue and the ﬁbrosis of extraocular
muscle and increase of orbital fat volume are characteristic histolog-
ical features of GO.10–13 There are many treatment modalities for GO
including systemic corticosteroids, orbital radiation, systemic
immunotherapy, and, recently, cytokines or B cell target therapy.
Generally speaking, systemic corticosteroid remains the treatment
of choice for GO. Systemic corticosteroids are sometimes effective,
but the ﬂare-up of symptoms is not uncommon during the tapering,
or withdrawal of corticosteroids. In this issue, the efﬁcacy of the
combination of orbital radiation and intravenous corticosteroids
for patients with refractory GO was investigated. Six patients with
active moderate-to-severe GO refractory to corticosteroid therapy
were treated with combined orbital radiotherapy and systemic cor-
ticosteroids. All patients achieved complete cessation of corticoste-
roid therapy and stabilization of disease without recurrence. The
authors concluded that combined orbital radiotherapy and systemic
corticosteroids can achieve greater improvement in clinical activity,
soft tissue inﬂammation, and ocular motility. It can stabilize disease
without recurrence in patients with refractory GO.References
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